Biomarkers of Ovarian Reserve | Zendy

William E. Roudebush | Zendy; Wendy J. Kivens | Zendy; Jessica M. Mattke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biomarkers of Ovarian Reserve

Author(s) -

William E. Roudebush,

Wendy J. Kivens,

Jessica M. Mattke

Publication year - 2008

Publication title -

biomarker insights

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.075

H-Index - 31

ISSN - 1177-2719

DOI - 10.4137/bmi.s537

Subject(s) - ovarian reserve , anti müllerian hormone , folliculogenesis , infertility , ovary , biomarker , andrology , medicine , hormone , physiology , menstrual cycle , biology , gynecology , embryo , endocrinology , pregnancy , embryogenesis , microbiology and biotechnology , biochemistry , genetics

The primary function of the female ovary is the production of a mature and viable oocyte capable of fertilization and subsequent embryo development and implantation. At birth, the ovary contains a finite number of oocytes available for folliculogenesis. This finite number of available oocytes is termed "the ovarian reserve". The determination of ovarian reserve is important in the assessment and treatment of infertility. As the ovary ages, the ovarian reserve will decline. Infertility affects approximately 15%-20% of reproductive aged couples. The most commonly used biomarker assay to assess ovarian reserve is the measurement of follicle stimulating hormone (FSH) on day 3 of the menstrual cycle. However, anti-müllerian hormone and inhibin-B are other biomarkers of ovarian reserve that are gaining in popularity since they provide direct determination of ovarian status, whereas day 3 FSH is an indirect measurement. This review examines the physical tools and the hormone biomarkers used to evaluate ovarian reserve.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research